| 1 | finished products manufacturing facility | | | | | | | 4 | 0.55% |
| 2 | partnering with novugen biz | | | | | | | 3 | 0.41% |
| 3 | oncology finished products manufacturing | | | | | | | 3 | 0.41% |
| 4 | supplier code of conduct | | | | | | | 2 | 0.28% |
| 5 | manufacturing facility commenced its | | | | | | | 2 | 0.28% |
| 6 | establishment of novugen pharma | | | | | | | 2 | 0.28% |
| 7 | novugen pharma finished products | | | | | | | 2 | 0.28% |
| 8 | usfda approval for novugen | | | | | | | 2 | 0.28% |
| 9 | novugen pharma manufacturing facility | | | | | | | 2 | 0.28% |
| 10 | products manufacturing facility commenced | | | | | | | 2 | 0.28% |
| 11 | general pharmaceutical manufacturing facility | | | | | | | 2 | 0.28% |
| 12 | teamwork is key in | | | | | | | 1 | 0.14% |
| 13 | that teamwork is key | | | | | | | 1 | 0.14% |
| 14 | i believe that teamwork | | | | | | | 1 | 0.14% |
| 15 | is key in many | | | | | | | 1 | 0.14% |
| 16 | key in many successes | | | | | | | 1 | 0.14% |
| 17 | it is impossible for | | | | | | | 1 | 0.14% |
| 18 | believe that teamwork is | | | | | | | 1 | 0.14% |
| 19 | newsroom careers contact us | | | | | | | 1 | 0.14% |
| 20 | of the highest quality | | | | | | | 1 | 0.14% |
| 21 | medicines of the highest | | | | | | | 1 | 0.14% |
| 22 | early access to affordable | | | | | | | 1 | 0.14% |
| 23 | impossible for us to | | | | | | | 1 | 0.14% |
| 24 | provide early access to | | | | | | | 1 | 0.14% |
| 25 | to provide early access | | | | | | | 1 | 0.14% |
| 26 | common cause to provide | | | | | | | 1 | 0.14% |
| 27 | a common cause to | | | | | | | 1 | 0.14% |
| 28 | in a common cause | | | | | | | 1 | 0.14% |
| 29 | united in a common | | | | | | | 1 | 0.14% |
| 30 | skilled professionals we stand | | | | | | | 1 | 0.14% |
| 31 | is impossible for us | | | | | | | 1 | 0.14% |
| 32 | in silos and expect | | | | | | | 1 | 0.14% |
| 33 | for us to work | | | | | | | 1 | 0.14% |
| 34 | work and i am | | | | | | | 1 | 0.14% |
| 35 | novugen oncology manufacturing facility | | | | | | | 1 | 0.14% |
| 36 | for novugen oncology manufacturing | | | | | | | 1 | 0.14% |
| 37 | approval for novugen oncology | | | | | | | 1 | 0.14% |
| 38 | the results of my | | | | | | | 1 | 0.14% |
| 39 | see the results of | | | | | | | 1 | 0.14% |
| 40 | to see the results | | | | | | | 1 | 0.14% |